Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence

Bohbot, Jean-Marc; Daraı̈, Émile; Bretelle, Florence; Brami, G.; Daniel, Christelle; Cardot, Jean‐Michel

doi:10.1016/j.jogoh.2017.11.005

Cited by 67 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The search identified 2949 unique articles but only 34 studies were eligible (flow diagram in Figure ) . Thirteen studies reported 14 results on BV and/or molecular VMB composition (Table ), 12 studies reported 12 results on VVC (Table ), and 14 studies reported 15 results on vaginal probiotic strain detection using molecular techniques (Table S1). The selected studies evaluated 22 different vaginal probiotics (Table S2).…”

Section: Resultsmentioning

confidence: 99%

“…Most studies (11/13) were randomised controlled trials, including six with placebo controls, two with ‘no intervention’ controls, four with metronidazole or clindamycin controls, and one with a vaginal pH‐lowering tablet control (two trials included both placebo/‘no intervention’ and antibiotic controls) (Table ). Five clinical trials were judged medium risk and the other six high risk . The two remaining studies (both judged high risk) were pre‐post intervention studies in women receiving a vaginal probiotic without an antibiotic …”

Section: Resultsmentioning

confidence: 99%

“…The two pre‐post intervention studies enrolled women with a range of baseline Nugent scores and showed significantly higher proportions of women with Nugent 0–3 immediately after cessation of probiotic use, which lasted up to 21–28 days post‐treatment . Of the nine BV recurrence results in eight randomised controlled trials, six were significant reductions, two non‐significant reductions, and one no reduction . The one study that showed no reduction in BV recurrence included women who used the vaginal probiotic during menses only .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Lactobacilli‐containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs

Wijgert

Verwijs

2019

BJOG

113

View full text Add to dashboard Cite

Background Vaginal probiotics claiming to cure and/or prevent bacterial and/or fungal vaginal dysbiosis are available on the market but, until recently, did not have to be approved as drugs for human use. Objectives We evaluated the impact of vaginal probiotics on bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) cure and/or recurrence, as well as vaginal microbiota (VMB) composition and vaginal detection of probiotic strains. Search strategy We performed a systematic literature search in MEDLINE and Embase up to 15 January 2019. Selection criteria There were no restrictions in probiotic strains/formulations, study populations, and designs. BV had to be diagnosed by Nugent or Ison‐Hay Gram stain scoring, VVC by culture, wet mount or PCR, and VMB composition/detection by molecular techniques. Data collection and analysis The authors independently extracted data. Main results All 22 vaginal probiotics evaluated in the 34 eligible studies contained Lactobacillus strains, and some contained additional active ingredients. The probiotics hold promise for BV cure and prevention, but much less so for VVC cure and prevention. No major safety concerns were reported in any of the studies. Vaginal detection of probiotic strains never lasted long beyond the dosing period, suggesting that they did not colonise the vagina. However, findings are not definitive because heterogeneity was high and the quality of most studies suboptimal. Conclusions Availability of vaginal probiotics for vaginal health indications will likely decline in 2020 because of regulatory changes. We urge the field to invest in clinical evidence‐based product development and to conduct future trials more rigorously. Tweetable abstract Lactobacilli‐containing vaginal probiotics hold promise for bacterial vaginosis cure and prevention, but not for vulvovaginal candidiasis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Lactobacilli‐containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs

Wijgert

Verwijs

2019

BJOG

113

View full text Add to dashboard Cite

show abstract

“…55 In addition to its presence as an indigenous bacterium in the vagina, some probiotic uses of L. crispatus have also been studied. 56 L. crispatus showed a protective effect in treatment of recurrent BV 57 and urinary tract infection (UTI). 58,59 The latter was supported by the observation that UTI recurrence was associated with abnormal vaginal flora.…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus crispatus accelerates re‐epithelialization in vaginal epithelial cell line MS74

Takada

Komine‐Aizawa

Kuramochi

et al. 2018

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…There was also a 28% longer time to reoccurrence in the probiotic group ( P = .0298). This study looked at adverse effects and found the overall tolerability to be 92.2% and did not find differences between the groups . This specific formulation is commercially available.…”

Section: Use Of Cam For Bvmentioning

confidence: 99%

Bacterial Vaginosis: A Clinical Update with a Focus on Complementary and Alternative Therapies

Falconi-McCahill¹

2019

J Midwife Womens Health

View full text Add to dashboard Cite

Bacterial vaginosis is a prevalent vaginal infection that affects women of all ages. Presenting symptoms include a vaginal discharge that is thin and white and has a fishy odor. This infection is associated with the acquisition of other sexually transmitted infections as well as premature labor and preterm birth. Recurrence rates after treatment are high, and medication adverse effects are common, leading many women to seek alternative therapies to manage and prevent recurrence. Many of these treatments are searchable online, and ingredients are easily obtainable. The purpose of this article is to review the state of the science regarding the safety and efficacy of alternative therapies for the treatment of bacterial vaginosis in nonpregnant women.

show abstract

Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence

Abstract: In women with recurrent BV after antibiotics, treatment with Lc IP 174178 administered over four menstrual cycles, could significantly reduce the rate of recurrence and increase the time to recurrence.

Cited by 67 publications

References 26 publications

Lactobacilli‐containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs

Lactobacilli‐containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs

Lactobacillus crispatus accelerates re‐epithelialization in vaginal epithelial cell line MS74

Bacterial Vaginosis: A Clinical Update with a Focus on Complementary and Alternative Therapies

Contact Info

Product

Resources

About